Navigation Links
Leading evolutionary scientist to discuss how genome of bacteria has evolved
Date:3/1/2012

RIVERSIDE, Calif. Nancy A. Moran, an internationally renowned expert on evolution, will give the 2012 Alfred M. Boyce Lecture at the University of California, Riverside on Monday, March 5.

The lecture, titled "Genome evolution in endosymbiotic bacteria," will take place at 4 p.m. in the Genomics Auditorium, Room 1102A, Genomics Building. The talk will be followed by a reception at 5 p.m. in the Entomology Building lobby. Both the talk and reception are free of charge and open to the public. Parking costs $6.

Endosymbiotic bacteria are bacteria that live only within specialized host cells. Symbiotic associations between insects and bacteria have evolved many times and are driven by a variety of effects of symbionts on hosts, including protection from enemies, manipulation of reproductive systems, and nutritional provisioning. Although these symbionts typically cannot be cultured, studies of their genomes have illuminated their biology and their functions in hosts. In her talk, Moran will share insights into general patterns of genome evolution gained from these studies.

Moran is the William H. Fleming Professor in the Department of Biology and Evolutionary Ecology at Yale University, where she has been since 2010. She received her Ph.D. in zoology from the University of Michigan in 1982, following which she became a National Academy of Sciences Scholar at the Institute of Entomology in Czechoslovakia. Later, she had a postdoctoral fellowship at Northern Arizona University. In 1986 she joined the faculty at the University of Arizona, where she worked her way through the professorial steps to become a Regents' Professor in 2001.

Moran's area of interest is the symbiotic relationshi
'/>"/>

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside
Source:Eurekalert

Page: 1 2

Related biology news :

1. Leading German Researcher awarded Elseviers 2011 Tetrahedron Prize
2. Verified Clinical Trials System Implemented at Leading Global Contract Research Organization to Improve Participant Safety and Data Integity
3. The leading edge of stress: New genomic, optogenetic and epigenetic findings
4. Evolution offers clues to leading cause of death during childbirth
5. Misleading morphology: 3 European parasitoid wasp species are seasonal forms of just 1
6. SomaLogic announces agreement with leading global pharma company to accelerate R&D
7. National labs leading charge on building better batteries
8. Joslin researchers identify pathways leading to activation of good fat
9. Firewood movement leading cause of oak infestation in San Diego County
10. John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting
11. Editor-in-chief of leading robotics journal responds to Obamas robotics initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Putnam Valley, NY. (June 26 , 2012) Researchers ... transplanting two varieties of stem cells into mouse cochlea ... cells and mouse embryonic stem (ES) cells demonstrate similar ... risk of tumor growth associated with transplanting iPS cells ...
... NEVERS, France, June 26, 2012 Polar ( ... assessment technology, together with LOOK , the inventor and ... of the first clipless cycling pedals to measure cycling power ... left/right balance and power output, and send the data directly ...
... discovered a new flu-fighting role for a well-known component ... cellular biology in the UGA Franklin College of Arts ... cell-signaling protein known as IL-15 to mice infected with ... times. "We gave the IL-15 intranasally and ...
Cached Biology News:Stem cell transplantation into mouse cochlea may impact future hearing loss therapies 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 3Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 4UGA study reveals flu-fighting role for well-known immune component 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Aug. 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ... company,focused on commercializing proprietary product candidates for ... announced that the U.S. Food and,Drug Administration ... ANX-510,or CoFactor(R) injection, which is currently being ...
... Drug Application in the Fourth ... ... positive results from a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal ... chronic non-cancer pain,conditions. The study achieved statistical significance on the primary,endpoint. Results ...
... Presentations on the Topic of Drug Repurposing and ... Indian Clinical ... Inc., an,oncology-focused, clinical-stage biopharmaceutical company, announced today,that Chief Executive Officer, ... present at the 234th American Chemical,Society National Meeting on Sunday, ...
Cached Biology Technology:ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
...
Biology Products: